Stratipath Breast AI-based risk profiling for breast cancer is now available for clinical use in the UK.
1 June 2024
Stratipath Breast, is now officially registered with the Medicines and
Being a leader in the field of AI-based precision diagnostics, Stratipath is constantly moving forward and evolving to provide new tools and strategies for improving patient outcomes. Keep track of developments in our news feeds, or follow us on LinkedIn or Twitter.
Being a leader in the field of AI-based precision diagnostics, Stratipath is constantly moving forward and evolving to provide new tools and strategies for improving patient outcomes. Keep track of developments in our news feeds, or follow us on LinkedIn or Twitter.
Stratipath Breast, is now officially registered with the Medicines and
Stratipath co-founder Professor Johan Hartman, is discussing the future of
Stratipath is the winner of the Health Tech Award 2024
Mattias Rantalainen, co-founder, CTO of Stratipath, and coordinator of SwAIPP
MedTechLabs labs recently interviewed our CEO, Fredrik Wetterhall, discussing the
Stratipath is proud to be a part of Proscia’s new
Stratipath, today announced that Stratipath Breast has received CE marking
new validation data for prognostic performance of Stratipath Breast in
Helsinki University Hospital (HUS), Finland’s largest healthcare provider and one
First world health tech: Press Release Stratipath releases biopsy capability
The ESMO Daily Reporter recently published a summary of the
A method for spatial interpretation of weakly supervised deep learning